SAN JOSE, Calif., Nov. 20, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with Moffitt Cancer Center, to advance toward human clinical testing, a Chimeric Antigen Receptor...
|
Press Release
|